aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-11-11 13:45Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the efficacy of its drug Efzofitimod, which did not meet its primary endpoint in a recent study [2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for aTyr investors who were affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - Defendants allegedly made positive statements about Efzofitimod while concealing material adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop from $6.03 to $1.02, a decline of 83.2% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request the Court to appoint them as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].